Focus on amphotericin B lipid complex: For serious systemic mycoses in patients who are refractory to or intolerant of conventional amphotericin B

Formulary

Volumn 31, Issue 3, 1996, Pages 169-185

  Wong Beringer, Annie ^a   Beringer, Paul M ^a   Rho, Jay P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0345025092     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Lopez-Berestein G, Mehta R, Hopfer RL, et al. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B J Infect Dis 1983;147:939-45.
2. Gallis H, Drew R, Pickard W. Amphotericin B: Thirty years of clinical experience. Rev Infect Dis 1990;12:308-29.
3. Kan VL, Bennett JE, Amantea MA, et al. Comparative safety and pharmacokinetic study of amphotericin B lipid complex and amphotericin B desoxycholate in healthy young male volunteers. J Infect Dis 1991;164:418-25.
4. Janknegt R, de Malie S, Bakker-Woudenberg I, et al. Liposomal and lipid formulations of amphotericin B: Clinical pharmacokinetics. Clin Pharmacokinet 1992;23:279-91.
5. Grasela D, Echevarria J, Summerill R, et al. Pharmacokinetics of amphotericin B following administration as amphotericin B lipid complex or fungizone in adults with mucocutaneous leishmaniasis [abstract no. 1439]. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. 1993 Oct 20; New Orleans.
6. Hiemenz JW, Lister J, Anaissie EJ, et al. Emergency-use amphotericin B lipid complex in the treatment of patients with aspergillosis: Historical-control comparison with amphotericin B [abstract no. 3383]. 37th Annual Meeting and Exposition of the American Society of Hematology. 1995 Dec 5; Seattle.
7. Walker RC, Hiemenz JW. Amphotericin B lipid complex in systemic mycoses refractory to amphotericin B [abstract no. 1724]. 31st Annual Meeting of the American Society of Clinical Oncology. 1995 May 23; Los Angeles.
8. Hiemenz JW, Anaissie EJ, Walsh TJ. Amphotericin B lipid complex for the treatment of severe systemic mycosis in patients with hematologic malignancies [abstract no. 1207]. 36th Annual Meeting and Exposition of the American Society of Hematology. 1994 Dec 5;Nashville.
9. Lister J. Amphotericin B lipid complex in the management of serious systematic mycoses in patients intolerant to amphotericin B therapy [abstract no. 1209]. 36th Annual Meeting and Exposition of the American Society of Hematology. 1994 Dec 5;Nashville.
10. Wingard JR, Walker RC. Efficacy of amphotericin B lipid complex in the treatment of bone marrow transplant recipients with life-threatening systemic mycoses [abstract no. 1928]. 36th Annual Meeting and Exposition of the American Society of Hematology. 1994 Dec 5;Nashville.
11. Walsh TJ, Hiemenz JW, Seibel N, et al. Amphotericin B complex in the treatment of 228 cases of invasive mycosis [abstract no. M69]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1994 Oct 7; Orlando.
12. Anaissie EJ, Ramphal R. Efficacy and safety of amphotericin B lipid complex in the treatment of patients with life-threatening fusariosis [abstract no. M87]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1994 Oct 7; Orlando.
13. Mehta J, Kelsey SM, Chu P, et al. Amphotericin B lipid complex for fungal sepsis in immunocompromised patients [abstract no. 2042]. 37th Annual Meeting and Exposition of the American Society of Hematology. 1995 Dec 5; Seattle.
14. Oravcova E, Mistrik M, Sakalova A, et al. Amphotericin B lipid complex to treat invasive fungal infections in cancer patients: Report of efficacy and safety in 20 patients. Chemotherapy 1995;41:473-6.
15. Anaissie EJ, White MH, Uzun O, et al. Amphotericin B lipid complex vs amphotericin B for treatment of hematogenous invasive candidiasis: A prospective, randomized multicenter trial [abstract no.LM21]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1995 September 18; San Francisco.
16. Naguib MT, Huycke MM, Pederson JA, et al. Apophysomyces elegans infection in a renal transplant recipient. Am J Kidney Dis 1995;26:381-4.
17. Hospenthal DR, Byrd JC, Weiss RB. Successful treatment of invasive aspergillosis complicating prolonged treatment-related neutropenia in acute myelogenous leukemia with amphotericin B lipid complex. Med Pediatr Oncol 1995;25:119-22.
18. Jones RS, Barman A, Suh B, et al. Successful treatment of Aspergillus vertebral osteomyelitis with amphotericin B lipid complex. Infect Dis Clin Pract 1995;4:237-9.
19. Churchill DN, Seely J. Nephrotoxicity associated with combined gentamicin-amphotericin B therapy. Nephron 1977;19:176-81.
20. Kennedy MS, Deeg HJ, Siegel M, et al. Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation. Transplantation 1983;35:211-5.
21. Kline S, Larsen TA, Fieber L, et al. Limited toxicity of prolonged high-dose amphotericin B lipid complex therapy. Clin Infect Dis 1995;21:1154-8.
22. Prescribing information, amphotericin B lipid complex (Abelcet), The Liposome Company, Princeton, NJ, November 1995.
23. Miller RP, Bates JH. Amphotericin B toxicity: A follow-up report of 53 patients. Ann Intern Med 1969;71:1089-95.
24. Wright DG, Robichaud KJ, Pizzo PA, et al. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med 1981;304:1185-9.